skip to Main Content

Addition of Adjuvant Capecitabine to Gemcitabine Improves Survival in Patients With Resected Pancreatic Cancer

Newsfeed image, light gray text on dark gray background
In the European phase III ESPAC-4 trial reported in The Lancet, John P. Neoptolemos, MD, of the Liverpool Clinical and Cancer Research UK Trials Unit, University of Liverpool, and colleagues found that adding adjuvant capecitabine to gemcitabine significantly improved overall survival in patients with resected pancreatic cancer.

In the open-label trial, 730 patients from 92 hospitals in England, Scotland, Wales, Germany, France, and Sweden were randomized between November 2008 and September 2014 within 12 weeks of surgery to receive 6 cycles of either 1,000 mg/m2 of gemcitabine alone given once a week for 3 of every 4 weeks in each cycle (n = 366) or with 1,660 mg/m2 of oral capecitabine given for 21 days followed by 7 days off in each cycle (n = 364). Read more . . .

Back To Top